Hypertrophic Cardiomyopathy Research 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Disease features and management of cardiomyopathies in women
AbstractOver the last years, there has been a growing interest in the clinical manifestations and outcomes of cardiomyopathies in women. Peripartum cardiomyopathy is the only women-specific cardiomyopathy. In cardiomyopathies with X-linked transmission, women are not simply healthy carriers of the disorder, but can show a wide spectrum of clinical manifestations ranging from mild to severe manifestations because of heterogeneous patterns of X-chromosome inactivation. In mitochondrial disorders with a matrilinear transmission, cardiomyopathy is part of a systemic disorder affecting both men and women. Even some inherited ca...
Source: Heart Failure Reviews - February 3, 2024 Category: Cardiology Source Type: research
Understanding the structural and functional changes and biochemical pathomechanism of the cardiomyopathy-associated p.R123W mutation in human αB-crystallin
In this study, human αB-crystallin was expressed in Escherichia coli (E. coli), and the missense mutation p.R123W was created using site-directed mutagenesis. Following purification via anion exchange chromatography, the structural and functional properties of both proteins were investigated and compared using a wide range of spectroscopic and microscopic methods. The p.R123W mutation induced significant alterations in the secondary, tertiary, and quaternary structures of human αB-crystallin. This pathogenic mutation resulted in an increased β-sheet structure and formation of protein oligomers with larger sizes compared...
Source: Biochimica et Biophysica Acta - February 2, 2024 Category: Biochemistry Authors: Leila Rezaei Somee Anis Barati Mohammad Bagher Shahsavani Masaru Hoshino Jun Hong Ashutosh Kumar Ali Akbar Moosavi-Movahedi Massoud Amanlou Reza Yousefi Source Type: research
Expression of Circulating miR-21 and -29 and their Association with Myocardial Fibrosis in Hypertrophic Cardiomyopathy
CONCLUSION: MiR-21 was overexpressed in patients with HCM and hypertensive cardiomyopathy. Importantly, in patients with HCM, more extensive myocardial fibrosis was associated with higher levels of miR-21.PMID:38299392 | DOI:10.2174/0109298673286017240103073130 (Source: Current Medicinal Chemistry)
Source: Current Medicinal Chemistry - February 1, 2024 Category: Chemistry Authors: Andreas Angelopoulos Evangelos Oikonomou Alexios Antonopoulos Panagiotis Theofilis Konstantinos Zisimos Ourania Katsarou Maria Gazouli George Lazaros Paraskevi Papanikolaou Gerasimos Siasos Dimitrios Tousoulis Konstantinos Tsioufis Charalambos Vlachopoulo Source Type: research
Cardiotoxicity Risk of Cancer Treatment in Patients With Underlying Cardiomyopathies: Is Hypertrophic Cardiomyopathy Any Different?
Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiomyopathy, and is characterized by pathologic left ventricular (LV) hypertrophy with different subtypes, such as apical HCM and septal HCM, with or without LV outflow tract obstruction (LVOTO).1 Worldwide, HCM has an estimated prevalence of 1 in 500 individuals (0.2% of the population).2 Symptoms of HCM are frequently related to dynamic LVOTO or diastolic dysfunction. Diastolic dysfunction can progress to the point of restrictive hemodynamics with a phenotype that mimics heart failure with preserved ejection fraction. (Source: Mayo Clinic Proceedings)
Source: Mayo Clinic Proceedings - February 1, 2024 Category: Internal Medicine Authors: Muhannad Aboud Abbasi, Edward El-Am, Jeffrey B. Geske, Joerg Herrmann Tags: Editorial Source Type: research
Genotype Influences Mavacamten Responsiveness in Obstructive Hypertrophic Cardiomyopathy
Mavacamten is a cardiac myosin inhibitor that reduces left ventricular outflow tract (LVOT) gradient in patients with obstructive hypertrophic cardiomyopathy (oHCM), thereby potentially lessening the need for septal reductive therapy (SRT).1,2 However, the factors that govern mavacamten response remain poorly understood. (Source: Mayo Clinic Proceedings)
Source: Mayo Clinic Proceedings - February 1, 2024 Category: Internal Medicine Authors: John R. Giudicessi, Said Alsidawi, Jeffrey B. Geske, Darrell B. Newman, Adelaide M. Arruda-Olson, J. Martijn Bos, Steve R. Ommen, Michael J. Ackerman Tags: Research Letter Source Type: research
